Incidence and Management of Driveline Infection in Patients with CH-VAD
NCT ID: NCT06878456
Last Updated: 2025-03-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
181 participants
OBSERVATIONAL
2017-06-01
2024-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main question it aims to answer is : The incidence of DLI in Chinese CH-VAD implanted advanced heart failure patients and the main risk factors.
CH-VAD has been approved in China for the treatment of patients with advanced heart failure.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Postoperative Infections and Immune Profiles in Patients Undergoing LVAD Implantation
NCT07255716
Efficacy of Self-expandable and Balloon-expandable Valves in Patients With Ascending Aortic Dilation
NCT06743568
Impact of LVAD Implantation on Micro- and Macrovascular Function
NCT02174133
Safety and Efficacy Continued Access Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in Very High Risk Subjects and High Risk Subjects Who Need Aortic Valve Replacement
NCT01531374
Safety and Efficacy of Post-marketing Transcatheter Aortic Valves in "Real World" Chinese Patients
NCT06257043
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
2. Study Design
* Design Type: Retrospective, observational, multicenter study.
* Study Population: 181 consecutive patients who received CH-VAD implantations between June 2017 and October 2024 at 9 centers in China.
* Primary Objective: To evaluate the incidence of DLI in CH-VAD patients.
* Secondary Objectives: To identify factors associated with DLI, assess the management strategies, evaluate patient outcomes, and detect risk factors for DLI.
3. Study Population
• Inclusion Criteria:
* Patients who received CH-VAD implantations for advanced heart failure (AHF) between June 2017 and October 2024.
• Exclusion Criteria:
* No specific exclusion criteria.
4. Data Collection
* Demographic and clinical characteristics from medical records, including age, sex, comorbidities, heart failure etiologies, INTERMACS profiles.
* Surgical details, including device type, duration of support, and concomitant surgeries.
* Infection prevention measures, including the use of prophylactic antibiotics, skin decolonization procedures, driveline fixation sutures, etc.
* Driveline care measures, including dressing change frequency, types of disinfectants, dressing types, fixation measures, etc.
* Incidence and management of DLI, including diagnostic methods, treatment approaches, and outcomes.
* Information on the pathogens involved in DLI and complications such as recurrent infections, driveline revisions, and mortality.
5. Statistical Analysis
* Descriptive statistics will be used to summarize patient demographics, DLI incidence, and outcomes.
* Univariate and multivariate regression analyses will be conducted to identify potential risk factors for DLI.
* Time-to-event analysis will be performed using Kaplan-Meier curves to evaluate freedom from DLI over time.
* Statistical significance will be set at p\<0.05.
6. Expected Outcomes and Significance
* Primary Outcome: Incidence of DLI in patients with CH-VAD.
* Secondary Outcomes: Risk factors associated with DLI, the impact of DLI on patient outcomes, and the effectiveness of different management strategies.
* The findings from this study could provide valuable insights into the clinical management of CH-VAD patients and inform future advancements in LVAD design to minimize DLI.
7. Timeline
* Study Period: June 2017 to October 2024 (Data collection period).
* Data Analysis Period: November 2024 to January 2025.
* Results Publication: Expected by March 2025.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wuhan Asia Heart Hospital
OTHER
Sichuan Provincial People's Hospital
OTHER
Zhejiang Provincial People's Hospital
OTHER
Ruijin Hospital
OTHER
Shanghai Zhongshan Hospital
OTHER
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER
First Affiliated Hospital Xi'an Jiaotong University
OTHER
China National Center for Cardiovascular Diseases
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shengshou Hu
Academician of Chinese Academy of Engineering
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fuwai Hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Wang X, Zhou X, Chen H, Zhang H, Zhang Y, Cui Y, Huang K, Hua Z, Yan Y, Zhou M, Zhao Q, Sun X, Wang C, Ge Z, Dong A, Hu S. Low driveline infection rates in patients with a novel fully magnetically levitated ventricular assist device. Eur J Cardiothorac Surg. 2025 Oct 25:ezaf365. doi: 10.1093/ejcts/ezaf365. Online ahead of print.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
China-NCCD
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.